Bile Microbiome Signatures Associated with Pancreatic Ductal Adenocarcinoma Compared to Benign Disease: A UK Pilot Study

被引:5
|
作者
Merali, Nabeel [1 ,2 ,3 ]
Chouari, Tarak [2 ,3 ]
Terroire, Julien [4 ,5 ]
Jessel, Maria-Danae [3 ]
Liu, Daniel S. K. [6 ]
Smith, James-Halle [7 ]
Wooldridge, Tyler [3 ]
Dhillon, Tony [3 ]
Jimenez, Jose I. [8 ]
Krell, Jonathan [6 ]
Roberts, Keith J. [7 ]
Rockall, Timothy A. [1 ]
Velliou, Eirini [9 ]
Sivakumar, Shivan [10 ]
Giovannetti, Elisa [11 ,12 ]
Demirkan, Ayse [4 ,5 ]
Annels, Nicola E. [3 ]
Frampton, Adam E. [1 ,2 ,3 ,6 ]
机构
[1] Royal Surrey Cty Hosp NHS Fdn Trust, Minimal Access Therapy & Training Unit MATTU, Leggett Bldg, Guildford GU2 7XX, England
[2] Royal Surrey Cty Hosp NHS Fdn Trust, Dept Hepatopancreato Biliary HPB Surg, Guildford GU2 7XX, England
[3] Univ Surrey, Fac Hlth & Med Sci, Dept Clin & Expt Med, Sect Oncol, Guildford GU2 7WG, England
[4] Univ Surrey, Surrey Inst People Centred AI, Guildford GU2 7XH, England
[5] Univ Surrey, Fac Hlth & Med Sci, Dept Clin & Expt Med, Sect Stat Multi, Guildford GU2 7WG, England
[6] Imperial Coll London, Div Canc, Dept Surg & Canc, Hammersmith Hosp Campus, London W12 0NN, England
[7] Univ Birmingham, Queen Elizabeth Hosp Birmingham, Coll Med & Dent Sci, Hepatobiliary & Pancreat Surg Unit, Birmingham B15 2TH, England
[8] Imperial Coll London, Dept Life Sci, London SW7 2AZ, England
[9] Univ Coll London UCL, Ctr 3D Models Hlth & Dis, Dept Targeted Intervent, Div Surg & Intervent Sci, London W1W 7TY, England
[10] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham Med Sch, Oncol Dept, Birmingham B15 2TT, England
[11] VU Univ Med Ctr Canc Ctr Amsterdam, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands
[12] Fdn Pisana Sci, AIRC Start Unit, Canc Pharmacol Lab, San Giuliano Terme PI, I-56017 Pisa, Italy
关键词
pancreatic cancer; microbiome; 16S rRNA gene; bile; biomarker; TUMOR MICROBIOME; CANCER; GEMCITABINE;
D O I
10.3390/ijms242316888
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) has a very poor survival. The intra-tumoural microbiome can influence pancreatic tumourigenesis and chemoresistance and, therefore, patient survival. The role played by bile microbiota in PDAC is unknown. We aimed to define bile microbiome signatures that can effectively distinguish malignant from benign tumours in patients presenting with obstructive jaundice caused by benign and malignant pancreaticobiliary disease. Prospective bile samples were obtained from 31 patients who underwent either Endoscopic Retrograde Cholangiopancreatography (ERCP) or Percutaneous Transhepatic Cholangiogram (PTC). Variable regions (V3-V4) of the 16S rRNA genes of microorganisms present in the samples were amplified by Polymerase Chain Reaction (PCR) and sequenced. The cohort consisted of 12 PDAC, 10 choledocholithiasis, seven gallstone pancreatitis and two primary sclerosing cholangitis patients. Using the 16S rRNA method, we identified a total of 135 genera from 29 individuals (12 PDAC and 17 benign). The bile microbial beta diversity significantly differed between patients with PDAC vs. benign disease (Permanova p = 0.0173). The separation of PDAC from benign samples is clearly seen through unsupervised clustering of Aitchison distance. We found three genera to be of significantly lower abundance among PDAC samples vs. benign, adjusting for false discovery rate (FDR). These were Escherichia (FDR = 0.002) and two unclassified genera, one from Proteobacteria (FDR = 0.002) and one from Enterobacteriaceae (FDR = 0.011). In the same samples, the genus Streptococcus (FDR = 0.033) was found to be of increased abundance in the PDAC group. We show that patients with obstructive jaundice caused by PDAC have an altered microbiome composition in the bile compared to those with benign disease. These bile-based microbes could be developed into potential diagnostic and prognostic biomarkers for PDAC and warrant further investigation.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Bile microbiome signatures as biomarkers for differentiating pancreatic ductal adenocarcinoma from benign disease.
    Merali, Nabeel
    Terroire, Julien
    Jessel, Maria-Danae
    Liu, Daniel
    Krell, Jonathan
    Lythgoe, Mark
    Demirkan, Ayse
    Frampton, Adam E.
    HUMAN HEREDITY, 2023, 88 (SUPPL 1) : 56 - 56
  • [2] Alterations of the bile microbiome is associated with progression-free survival in pancreatic ductal adenocarcinoma patients
    Jiang, Hang
    Tian, Yitong
    Xu, Linwei
    Chen, Xing
    Huang, Yurun
    Wu, Jia
    Wang, Tingzhang
    Liu, Tingting
    Wu, Xitian
    Ye, Chao
    Wu, Hao
    Ye, Wenkai
    Fang, Luo
    Zhang, Yuhua
    BMC MICROBIOLOGY, 2024, 24 (01):
  • [3] Proteomic Analysis of Pancreatic Ductal Adenocarcinoma Compared with Normal Adjacent Pancreatic Tissue and Pancreatic Benign Cystadenoma
    Cui, Yazhou
    Tian, Mei
    Zong, Meijuan
    Teng, Mujian
    Chen, Yu
    Lu, Jun
    Jiang, Jinbo
    Liu, Xiaoyong
    Han, Jinxiang
    PANCREATOLOGY, 2009, 9 (1-2) : 89 - 98
  • [4] Super-enhancer signatures of pancreatic ductal adenocarcinoma and associated fibroblasts
    Hussein, Shaimaa
    Noel, Pawan
    Chen, Kenian
    Metang, Lauren
    Von Hoff, Daniel
    Han, Haiyong
    Lin, Yin
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [5] Dynamics of intestinal and intratumoral microbiome signatures in genetically engineered mice and human pancreatic ductal adenocarcinoma
    Pfisterer, Nina
    Ammer-Herrmenau, Christoph
    Antweiler, Kai
    Kueffer, Stefan
    Ellenrieder, Volker
    Neesse, Albrecht
    PANCREATOLOGY, 2023, 23 (06) : 663 - 673
  • [6] GNAS Mutations in Concomitant Pancreatic Ductal Adenocarcinoma: A Pilot Study
    Fazlollahi, L.
    Dias-Santagata, D.
    Sahora, K.
    Morales-Oyarvide, V.
    Bernardo, L. A.
    Iafrate, A. J.
    Pitman, M. B.
    Fernandez-del Castillo, C.
    Mino-Kenudson, M.
    LABORATORY INVESTIGATION, 2013, 93 : 424A - 424A
  • [7] GNAS Mutations in Concomitant Pancreatic Ductal Adenocarcinoma: A Pilot Study
    Fazlollahi, L.
    Dias-Santagata, D.
    Sahora, K.
    Morales-Oyarvide, V.
    Bernardo, L. A.
    Iafrate, A. J.
    Pitman, M. B.
    Fernandez-del Castillo, C.
    Mino-Kenudson, M.
    MODERN PATHOLOGY, 2013, 26 : 424A - 424A
  • [8] Ciprofloxacin plus gemcitabine-based chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma: A pilot study of microbiome manipulation
    Cheo, Seng Wee
    Lee, Jonathan W. J.
    Walsh, Robert John
    Sundar, Raghav
    Choo, Joan R. E.
    Chan, Gloria
    Yong, Wei-Peng
    Meah, Wee Yang
    Khor, Chiea Chuen
    Chee, Cheng Ean
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] A Pilot Study to Develop a Diagnostic Test for Pancreatic Ductal Adenocarcinoma Based on Differential Expression of Select miRNA in Plasma and Bile
    Cote, Gregory A.
    Gore, A. Jesse
    McElyea, Samantha D.
    Heathers, Laura E.
    Xu, Huiping
    Sherman, Stuart
    Korc, Murray
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (12): : 1942 - 1952
  • [10] DWI of Pancreatic Ductal Adenocarcinoma: A Pilot Study to Estimate the Correlation With Metastatic Disease Potential and Overall Survival
    Garces-Descovich, Alejandro
    Morrison, Trevor C.
    Beker, Kevin
    Jaramillo-Cardoso, Adrian
    Moser, A. James
    Mortele, Koenraad J.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2019, 212 (02) : 323 - 331